Here's Why SpringWorks Therapeutics Climbed 69% in December [The Motley Fool]
SpringWorks Therapeutics, Inc. - common stock (SWTX)
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm
Check Earnings Report
Company Research
Source: The Motley Fool
Here's Why SpringWorks Therapeutics Climbed 69% in December The stock climbed after investors saw encouraging signs from a similar program. Shares of SpringWorks Therapeutics ( NASDAQ:SWTX ) , a clinical-stage biopharmaceutical company, rose 68.7% in December, according to data from S&P Global Market Intelligence . It was a quiet month for specific news about a gamma-secretase inhibitor GlaxoSmithKline ( NYSE:GSK ) is developing in partnership with SpringWorks, but encouraging early results from a similar program provided the lift for SpringWorks stock. GlaxoSmithKline is developing belantamab mafodotin, a protein that delivers single-serving chemotherapy packages directly to tumor cells when it finds B-cell maturation antigen (BCMA) on their surface. In June, Glaxo agreed to fund early clinical-stage development of nirogacestat from SpringWorks because it could be an effective way to boost its belantamab mafodotin's efficacy. Nirogacestat inhibits gamma-secretase from removing BCMA
Show less
Read more
Impact Snapshot
Event Time:
SWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SWTX alerts
High impacting SpringWorks Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
SWTX
News
- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $75.00 price target on the stock, up previously from $70.00.MarketBeat
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]Yahoo! Finance
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business UpdatesGlobeNewswire
- SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear [Seeking Alpha]Seeking Alpha
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
SWTX
Earnings
- 5/2/24 - Beat
SWTX
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/5/24 - Form ARS
- SWTX's page on the SEC website